NEW YORK (GenomeWeb News) – Becton Dickinson yesterday filed a statement with the US Securities and Exchange Commission outlining its intention to purchase TriPath Imaging for approximately $350 million.
 
BD said it proposed to acquire approximately 93.5 percent of TriPath’s outstanding shares for $9.25 per share. BD and TriPath have been collaborating to identify cancer biomarkers since 2001, when BD acquired an approximately 6.5-percent equity stake in TriPath.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.